New Amendments to the European Cosmetic Regulation
Commission Regulation (EU) 2021/1099 of 5 July 2021 sets out that Deoxyarbutin should be prohibited in cosmetic products and that the use of Dihydroxyacetone should be restricted in non-oxidative hair dye products and in self-tanning products. This results in one new entry to Annex II and one new entry to Annex III of the European Cosmetic Regulation, respectively.

DEOXYARBUTIN AND DIHYDROXYACETONE

Deoxyarbutin (CAS No. 53936-56-4), chemically 4-[(tetrahydro-2H-pyran-2-yl)oxy]phenol (INCI name: Tetrahydropyranyloxy Phenol) is a cosmetic ingredient used as a bleaching agent. It is a skin lightening agent synthesized through removal of hydroxyl groups from the glucose side-chain of ß-arbutin.

In 2008, on its opinion on ß-arbutin, the Scientific Committee on Consumer Products (SCCP) raised concerns with other substances resulting in the release and/or formation of hydroquinone. Hydroquinone is prohibited in cosmetics products, as it is listed in Annex II (entry 1339) of the European Cosmetic Regulation No 1223/2009. As an exception, Hydroquinone is only permitted for professional use in artificial nail systems in a concentration in the final product up to 0.02% (Annex III, entry 14).

The European Commission’s Scientific Committee on Consumer Safety (SCCS), concluded in 2015 that, due to safety concerns raised with regard to the life cycle of products containing that substance, the use of Deoxyarbutin up to 3% in face creams cannot be considered as safe.

Dihydroxyacetone (DHA, CAS No: 96-26-4) is an aliphatic ketone that is used as a hair dyeing, skin conditioning and tanning agent in cosmetics and personal care products. This ingredient is used in self-tanning cosmetic products in the EU market since the 1960’s.

In 2010, the SCCS published an opinion on the use of DHA on cosmetic products and concluded that the use of this substance as a self-tanning ingredient in cosmetic formulations up to 10% and in spray cabins up to 14% would not pose a risk to the health of the consumer. In another opinion, issued in 2020, the SCCS considered that DHA is safe when used as a hair coloring ingredient in leave-on applications (non-oxidative) up to a maximum concentration of 6.25%. Moreover, the SCCS also concluded that the use of Dihydroxyacetone as a hair coloring ingredient in leave-on applications (non-oxidative) up to a maximum concentration of 6.25 % together with the use of self-tanning lotion and face cream containing up to a maximum concentration of 10% Dihydroxyacetone is also considered safe.

COMMISSION REGULATION (EU) 2021/1099

Until now, Deoxyarbutin and Dihydroxyacetone were not regulated in Regulation (EC) No 1223/2009.

On July 5 2021 the Commission Regulation (EU) 2021/1099, amending Annexes II and III of the European Cosmetic Regulation (EC) No 1223/2009, entered into force.

Based on the SCCS opinions on both substances, the Commission considers that:

  • Deoxyarbutin should be prohibited for use in cosmetic products and added to the list of prohibited substances (Annex II) of the Cosmetics Regulation.
  • It is necessary to add a new entry in Annex III of the Cosmetics Regulation, restricting the use Dihydroxyacetone in non-oxidative hair dye products and in self-tanning products only, in a maximum concentration of up to 6.25% and 10% respectively.

Appropriate and reasonable periods of time should be granted to industry in order to adapt to the new requirements on the use of Dihydroxyacetone in cosmetic products and to phase out the placing and making available on the market of cosmetic products which do not comply with those requirements.

If you wish to know more information about these ingredients or amendments to the Eurpean Cosmetic Regulation, feel free to contact us at info@criticalcatalyst.com.

References:

  1. Regulation (EC) No 1223/2009 of the European Parliament and of the Council of 30 November 2009 on cosmetic products.
  2. Commission Regulation (EU) 2021/1099 of 5 July 2021 amending Annexes II and III to Regulation (EC) No 1223/2009 of the European Parliament and of the Council on cosmetic products.

further
reading

medical devices

Safety Reporting in Clinical Investigations: a Gap Analysis of Guidance Documents 

Safety reporting in clinical investigations of medical devices shall be performed in line with Article 80(2) of the EU MDR. On May 2020, it was published the MDCG 2020-10/1, outlining the procedures for safety reporting in clinical investigations of medical devices under the EU MDR. However, on October 2022 the Medical Device Coordination Group (MDCG) published an updated version of the MDCG 2020-10/1, the MDCG 2020-10/1 Rev 1. This article highlights the updates included in the new revision, analysing the gaps between both documents.

Read More »
medical devices

Roles and Responsibilities of an Authorised Representative under EU MDR and IVDR 

If a medical device manufacturer is not established in a Member State, the devices can only be placed on the Union market if the manufacturer designates an authorised representative. The authorised representative plays a pivotal role in ensuring the compliance of the devices with EU regulation, serving as point of contact. The obligations and responsibilities of authorised representative are outlined on Article 11 of both MDR and IVDR, but clarification of relevant requirements is described in MDCG 2022-16 of October 2022.

Read More »
medical devices

Understanding the ISO Standards Lifecycle

ISO Standards cover a huge range of activities, representing the distilled wisdom of people with expertise in their subject matter and providing the regulators with a sound basis to develop better legislation. ISO Standards are diverse, addressing from the shoe size we wear to the quality of air we breathe. The medical device sector is no exception. ISO has many International Standards and guidance documents aimed at helping the sector ensure safe and effective medical devices while meeting the multitude of national, regional and international regulatory requirements. But how exactly is a Standard developed, reviewed and withdraw?

Read More »
medical devices

Amendments to the Transitional Provisions of the European Union MDR and IVDR

The proposed amendments aim to maintain patients’ access to a wide range of medical devices while ensuring the transition to the new framework. The ammendments proposal aims to extend the current transition period (Article 120 of the MDR), and it also deletes the ‘sell-off’ deadlines of both MDR and IVDR. The extension is staggered depending on the risk class of the device – until December 2027 for high-risk devices and December 2028 for medium and lower-risk devices.

Read More »
medical devices

EU MDR – Proposal for Extension of Transition Period

The transition to MDR has been slower than anticipated by the European Commission. Insufficient capacity of notified bodies and the low level of preparedness of manufacturers led to a proposal for extension of current MDR transition period with deadlines depending on the risk class of the devices.

Read More »
medical devices

MDCG 2022-18 – EU MDR Article 97

EU MDR Article 97 may be a temporary solution to avoid disruption of supply of Medical Devices on the EU Market. The MDCG 2022-18 presents a uniform approach for application of MDR Article 97 on non-compliant legacy devices under the conditions set by the competent authorities, while limiting the impact on the supply of safe and effective devices.

Read More »
parfum_fragrance_allergen_1
cosmetic products

EU to set Labelling Requirements for 56 additional Fragrance Allergens in Cosmetic Products

World Trade Organization (WTO) has been notified by the European Commission of a draft amendment to Regulation (EC) No 1223/2009 as regards labelling of fragrance allergens in Cosmetic Products. The proposed date of adoption of the new regulation is expected to be in the first half of 2023 and the propose date of entry in force 20 days from the publication in the Official Journal of the European Union.

Read More »
cosmetic products

New Amendments to the European Cosmetics Regulation – CMR Substances

The European Commission published the Commission Regulation (EU) 2022/1531, which amends Regulation (EC) No 1223/2009 in regards to the use in cosmetic products of certain substances classified as CMR. This amendment introduces new entries to Annex II and Annex III and revises an entry to Annex V to Regulation (EC) No 1223/2009.

Read More »